InsiderSignal.AI

InsiderSignal.ai

ZBIO - Zenas Biopharma, Inc.

Insider Purchase by Lu Hongbo (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Lu Hongbo, serving as Dir at Zenas Biopharma, Inc. (ZBIO), purchased 3,768 shares at $18.63 per share, for a total transaction value of $70,198.00. Following this transaction, Lu Hongbo now holds 426,736 shares of ZBIO.

This purchase represents a 1.00% increase in Lu Hongbo's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 31, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 2 days after the trade was made.

Zenas Biopharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Lu Hongbo

Dir

Hongbo Lu, Ph.D., MBA is a seasoned healthcare investor and independent director serving on the boards of several public biopharma companies, including Zenas BioPharma, Inc. (Nasdaq: ZBIO) since 2022, where she recently purchased 263,160 shares on October 7, 2025, for approximately $5 million.[[5]](https://www.quiverquant.com/news/Insider+Purchase:+Director+at+$ZBIO+Buys+263,160+Shares)[[1]](https://fintool.com/app/research/companies/ARWR/people/hongbo-lu)[[4]](https://www.nasdaq.com/market-activity/insiders/lu-hongbo-1077521) She also serves as a director at Terns Pharmaceuticals, Inc. (Nasdaq: TERN) since 2020 and joined Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) as an independent director in March 2024, contributing to the Science, Nomination, and Compensation Committees.[[1]](https://fintool.com/app/research/companies/ARWR/people/hongbo-lu)[[2]](https://arrowheadpharma.com/about/leadership-team/hongbo-lu/)[[6]](https://app.boardroomalpha.com/profiles/people/A1112719-HONGBO_LU) Dr. Lu brings over 20 years of experience in healthcare investment, having held key roles such as Managing Partner at Vivo Capital LLC (since December 2020), Managing Partner at Lilly Asia Ventures (2017–2020), and Managing Director at OrbiMed Advisors.[[1]](https://fintool.com/app/research/companies/ARWR/people/hongbo-lu)[[2]](https://arrowheadpharma.com/about/leadership-team/hongbo-lu/) She is a founding member of NEXTBio Capital and has served on more than 20 biopharma boards, including past positions at Turning Point Therapeutics and Avedro.[[2]](https://arrowheadpharma.com/about/leadership-team/hongbo-lu/) Her career began as a biotech analyst at Piper Jaffray & Co. and involved early-stage biotech operations.[[2]](https://arrowheadpharma.com/about/leadership-team/hongbo-lu/) Dr. Lu holds a Ph.D. in Bioengineering from the University of Washington, an MBA from UC Berkeley Haas School of Business, and is an honors graduate of Tsinghua University.[[1]](https://fintool.com/app/research/companies/ARWR/people/hongbo-lu)[[2]](https://arrowheadpharma.com/about/leadership-team/hongbo-lu/)

View full insider profile →

Trade Price

$18.63

Quantity

3,768

Total Value

$70,198.00

Shares Owned

426,736

Trade Date

Tuesday, March 31, 2026

5 days ago

SEC Filing Date

Thursday, April 2, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Zenas Biopharma, Inc.

Company Overview

No company information available
View news mentioning ZBIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5311953

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime